Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-22-089720)

NAMES OF REPORTING PERSONS

Vifor (International) Ltd.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☒ (b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Switzerland

Accession Number:: 0001193125-22-089720
Form Type:: 13G Filing
Publication Date:: 2022-03-29 20:00:00

Filed By:: Vifor (international) Ltd
Company:: Elicio Therapeutics Inc.
Filing Date:: 2022-03-30
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Vifor (International) Ltd	1,995,643	1,995,643	1,995,643	6.7%
Vifor Fresenius Medical Care Renal Pharma Ltd	0	0	1,995,643	6.7%
Vifor Pharma Ltd	1,995,643	1,995,643	1,995,643	6.7%

Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.__)*

Angion Biomedica Corp.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

03476J107

(CUSIP Number)

February 9, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 03476J107		SCHEDULE 13G		Page 1 of 7 Pages


CUSIP No. 03476J107		SCHEDULE 13G		Page 2 of 7 Pages


CUSIP No. 03476J107		SCHEDULE 13G		Page 3 of 7 Pages

(1)	Based on 29,956,483 shares of Common Stock outstanding as of November 5, 2021, based on the disclosure in the Issuers Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on November 12, 2021.

(2)

Vifor Fresenius Medical Care Renal Pharma Ltd.s beneficial ownership of the common stock referred to herein is being reported solely because Vifor Fresenius Medical Care Renal Pharma Ltd. may be deemed to beneficially own such shares as a result of its right to acquire such shares upon exercise of an option granted to it by Vifor (International) Ltd. Vifor Pharma Ltd.s beneficial ownership of the common stock referred to herein is being reported solely because Vifor Pharma Ltd. may be deemed to beneficially own such shares as a result of its indirect ownership of 100% of the equity interests of Vifor (International) Ltd. and 55% of the equity interests of Vifor Fresenius Medical Care Renal Pharma Ltd. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by Vifor Fresenius Medical Care Renal Pharma Ltd. or Vifor Pharma Ltd. that it is the beneficial owner of any of the common stock referred to herein for purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934 or for any other purpose, and such beneficial ownership is expressly disclaimed.


CUSIP No. 03476J107		SCHEDULE 13G		Page 4 of 7 Pages

Item 1(a).

Name of Issuer:

Angion Biomedica Corp. (the Issuer)

Item 1(b).

Address of Issuers Principal Executive Offices:

Angion Biomedica Corp.

51 Charles Lindbergh Boulevard

Uniondale, New York 11553

Item 2(a).

Name of Person Filing:

Vifor (International) Ltd.

Vifor Fresenius Medical Care Renal Pharma Ltd.

Vifor Pharma Ltd.

The foregoing persons are collectively referred to herein as the Reporting Persons.

Item 2(b).

Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

Rechenstrasse 37

CH-9014, St. Gallen

Switzerland

Item 2(c).

Citizenship:

The place of organization of each of the Reporting Persons is Switzerland.

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.01 per share

Item 2(e).

CUSIP Number:

03476J107

Item 3.

If this Statement is Filed Pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:


(a)	☐	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☐	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);


CUSIP No. 03476J107		SCHEDULE 13G		Page 5 of 7 Pages


(j)	☐	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4.

Ownership.

(a)

Amount beneficially owned:

(b)

Percent of class:

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

As of March 30, 2022, the Reporting Persons respective beneficial ownership was as follows:

(A)

Vifor (International) Ltd.

Amount beneficially owned: 1,995,643 shares

Percent of class: 6.7%

Sole voting power: 0 shares

Shared voting power: 1,995,643 shares

Sole dispositive power: 0 shares

Shared dispositive power: 1,995,643 shares

(B)

Vifor Fresenius Medical Care Renal Pharma Ltd.

Amount beneficially owned: 1,995,643 shares

Percent of class: 6.7%

Sole voting power: 0 shares

Shared voting power: 0 shares

Sole dispositive power: 0 shares

Shared dispositive power: 0 shares

(C)

Vifor Pharma Ltd.

Amount beneficially owned: 1,995,643 shares

Percent of class: 6.7%

Sole voting power: 0 shares

Shared voting power: 1,995,643 shares

Sole dispositive power: 0 shares

Shared dispositive power: 1,995,643 shares


CUSIP No. 03476J107		SCHEDULE 13G		Page 6 of 7 Pages

Item 5.

Ownership of Five Percent or Less of Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

See Exhibit A hereto.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


CUSIP No. 03476J107		SCHEDULE 13G		Page 7 of 7 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Dated: March 30, 2022	VIFOR (INTERNATIONAL) LTD.

	By:	/s/ Oliver Kronenberg
		Name: Oliver Kronenberg
		Title: Group General Counsel

	By:	/s/ Georg Frey
		Name: Georg Frey
		Title: Head Corporate Legal

Dated: March 30, 2022	VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD.

	By:	/s/ Oliver Kronenberg
		Name: Oliver Kronenberg
		Title: Group General Counsel

	By:	/s/ Georg Frey
		Name: Georg Frey
		Title: Head Corporate Legal

Dated: March 30, 2022	VIFOR PHARMA LTD.

	By:	/s/ Oliver Kronenberg
		Name: Oliver Kronenberg
		Title: Group General Counsel

	By:	/s/ Georg Frey
		Name: Georg Frey
		Title: Head Corporate Legal

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).